Kornimate/medical-research-clean huggingface dataset:
analyse cardio-respiratory patterns in order to early detect the clinical complications in the hemodialysis patients

Conditions: Chronic Kidney Disease

Summary: the incidence and prevalence of dialysis in taiwan remains higher as compared to past several years. the number of dialysis reported about 6-7 million people each year and the 2014 full-year cost estimation was about 330 million ntds. according to age-standardized population statistics in 1995, the number of dialysis per million population in 2006 year were 372.2 people, 381.9 people in 2012 year and the annual growth rate of 0.43 percent recorded. earlysense system is certified by tfda, fda and many other countries, which consists of mainly two parts. one for the sensing element, which placed under the mattress and the other one is ac-powered display panel bed. this system has the ability to monitor the patients physiological functions just be in contact via bed. when the patient laid on bed, the sensor which is placed under the bed would detects heart rate, breathing rate and activity level as well as other physiological signals. the system is also able to distinguish between patients in bed and out of bed during the operation to save the patient's records and information (including heart rate, respiratory rate and level of activity, and may render trends). the system is also have capability for real-time data transmission information which includes a warning to the nurses' station or other monitoring center of the screen by providing real-time information to nurse. in this research project, we will use earlysense equipment for continuous monitoring the dialysis patient's physiological data along with clinical data such as a. acute complications such as rapid changes in blood pressure, respiratory rate, movements of patients and nausea or vomiting, etc phenomenon's) b. lab examination data c. status of patient whether patients hospitalized or not and patient death occurred or not. the study is expected to have a pilot study for more than three months' duration. through this earlysense continuous monitoring and gather the data, we will analyse to develop a prediction model and confirmed with indicators. evidences from these analytics would help to propose ways to improve it and implement positive predictive validity models.


Eligibility criteria:
inclusion criteria: * above 20 years old and under hemodialysis exclusion criteria: * patient with coronary artery disease or under treatment for coronary artery disease and patient with fever, any kind of infection, or taking antibiotics
timolol gel for epistaxis in hereditary hemorrhagic telangiectasia

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: this study is a double-blinded, randomized controlled trial to evaluate the efficacy of an intranasal topical timolol gel in the care for epistaxis in adults with hereditary hemorrhagic telangiectasia.

this study is a double-blinded, placebo-controlled, 8-week randomized clinical trial investigating the efficacy of timolol gel in the management of epistaxis in adults with hht. the specific aims are to determine in adults with hht-associated epistaxis: 1. if topical timolol gel is more effective than placebo in reducing the frequency and severity of epistaxis. 2. if topical timolol gel is more effective than placebo in improving hemoglobin levels. 3. the frequency of adverse events, side effects, and safety profile of topical timolol gel delivered to the nasal mucosa.

Eligibility criteria:
inclusion criteria: 1. adults ages 20 and older 2. confirmed clinical (meeting at least 3 of the 4 curaçao criteria) or genetic diagnosis of hht 3. epistaxis severity score (ess) ≥ 4 and 2 or more nosebleeds per week with a cumulative nosebleed duration of at least 5 minutes per week 4. stable nasal hygiene and medical regimen for preceding 1 month 5. stable epistaxis pattern over the preceding 3 months exclusion criteria: 1. contraindications for systemic β adrenergic blocker administration 1. hypersensitivity to β adrenergic blockers 2. asthma or bronchospasm 3. congestive heart failure with lvef \<40% 4. hereditary pulmonary arterial hypertension 5. baseline bradycardia (hr \<55 beats per minute) 6. sick sinus syndrome 7. 2nd or 3rd degree heart block, left or right bundle branch block, or bifasicular block 8. uncontrolled diabetes mellitus (most recent hba1c \>9%) or diabetic ketoacidosis within last 6 months 9. hypotension (systolic blood pressure \< 90) 2. known hypersensitivity to timolol 3. severe peripheral circulatory disturbances (raynaud phenomenon) 4. known intermediate or poor metabolizer variant of the liver enzyme cyp2d6 5. current use of any of the following known strong cyp2d6 inhibitors: fluoxetine (prozac), paroxetine (paxil), bupropion (welbutrin), quinidine, quinine, ritonavir (norvir), and terbinafine (lamisil) 6. current use of the following other drugs known to pharmacodynamically interact with timolol: diltiazem, verapamil, digoxin, digitalis, propafenone, disopyramide, clonidine, flecainide, or lidocaine 7. patients currently treated or who plan to initiate treatment with β-blockers 8. use of any anti-angiogenic medication in the last month prior to recruitment, including bevacizumab, pazopanib, thalidomide, or lenalidomide 9. illicit drug use, except marijuana 10. known pheochromocytoma 11. use of anticoagulants, antiplatelet, or fibrinolytic therapies within the last month prior to recruitment, except for low-dose (81 mg or less) of aspirin 12. pregnancy or planned pregnancy in the next 6 months or currently breastfeeding 13. inability to read or understand english 14. inability to complete 8 weeks of therapy for any reason

Keywords: epistaxis
effect of a maintenance protocol after surgical treatment of peri-implantitis

Conditions: Peri-Implantitis

Summary: this study was designed as a 12-month, two arms, randomized clinical trial to evaluate the efficacy of a supportive treatment protocol (spit). thirty patients were randomized, six months after access-flap surgery, in two different spit groups. after ultrasonic debridement, the affected implant surfaces of the test group were treated with glycine powder air-polishing, while implants in the control group a rubber cup and polishing paste was used. maintenance visits were carried every 3 months and clinical, radiological, microbiological and biochemical variables were registered at baseline (6 months after surgery) and after a follow-up period of 12 months (18 months after surgery).

study design: this study was designed as a 12-month, two arms, rct to evaluate the efficacy of a spic protocol. thirty patients were randomized, six months after access-flap surgery, in two different spit groups. after ultrasonic debridement, the affected implant surfaces of the test group were treated with glycine powder air-polishing, while implants in the control group a rubber cup and polishing paste was used. maintenance visits were carried every 3 months and clinical, radiological, microbiological and biochemical variables were registered at baseline (6 months after surgery) and after a follow-up period of 12 months (18 months after surgery). interventions: at the 6-month evaluation after the surgery, the baseline data for the present study were obtained and patients were randomised using a computerized block randomization protocol to one of the following spic protocols. in the test group, implant surfaces were treated with glycine powder air-polishing after ultrasonic instrumentation; the specific nozzle was activated subgingivally and circumferentially around the implant for 1 minute. in the control group, implants were cleaned with a rubber cup and polishing paste after ultrasonic instrumentation. this spic visits were carried out at 6 (baseline visit), 9, 12, 15 and 18 months after surgery.

Eligibility criteria:
inclusion criteria: * presence of at least one implant with peri-implantitis, defined as: radiographic evidence of bone loss \>2 mm, inflammation of the peri-implant mucosa as defined by positive bop and/or suppuration, and at least one site with pd ≥ 5 mm. * based on the radiographic examination, the affected implant should not have a vertical peri-implant defect. positive selection was based on the presence of pe-ri-implant lesions wider than 4 mm, with an angle greater than 35 º. * in patients with a history of periodontitis, periodontal therapy should have been provided at least 6 months prior to the initiation of the study. exclusion criteria: * presence of relevant medical conditions and/or systemic medications that would contraindicate the surgical procedure or modify the tissue response after therapy. * patients requiring antibiotic prophylaxis. * heavy smokers (\> 10 cigarettes/day). * pregnant or lactating women
treatment of atraumatic rotator cuff rupture in elderly patients

Conditions: Atraumatic Rotator Cuff Rupture

Summary: the purpose of the investigators study is to compare the effect of: 1) physiotherapy 2) arthroscopic acromioplasty and debridement or 3) arthroscopic rotator cuff reconstruction and acromioplasty in the treatment of degenerative, atraumatic rotator cuff rupture.

the study will be conducted according to the revised declaration of helsinki by the world medical association and the ich-guidelines for good clinical trial practice. the study will be submitted for approval to the ethics committee of the hospital district of varsinais-suomi, finland. a written informed consent will be obtained from each patient. this study will be conducted at three different hospitals i.e. turku university hospital, tampere university hospital (hatanpää hospital) and kuopio university hospital as a multicenter study. a total of 180 patients, 60 patients at each hospital, will be included in this study. the patients are clinically examined and a routine x-ray and mri-investigation are performed. patients must have an atraumatic degenerative supraspinatus tendon rupture comprising less than 2/3 of the tendon insertion, i.e. 1/3 of the tendon insertion must be intact. the rupture must be documented by mri investigation. patients must be willing and give a written informed consent. after recruitment the patients are randomized in one of three studied treatment modalities. the randomization is made after clinical and mri investigation by neutral attendant using sealed envelopes. 60 identical envelopes (20 per group) are made in each center. the constant score is used as a primary outcome measure. the constant score is measured from each patient right before treatment intervention and at three and six months, one, two and five years after the intervention. the intervention groups are designed in a cumulative fashion: structured and standardized physiotherapy treatment proceeds gradually in all patients (groups 1,2,3), in addition to physiotherapy patients in group 2 are treated with acromioplasty, and patients in group 3 with acromioplasty and rotator cuff reconstruction.

Eligibility criteria:
inclusion criteria: 1. age over 55 years 2. atraumatic penetrating supraspinatus tendon rupture comprising less than 2/3 of the tendon insertion and documented with mri investigation. 3. full active range of motion 4. written informed consent from participating subject exclusion criteria: 1. age under 55 years 2. existing significant malignant, haematological, endocrine, metabolic, rheumatoid or gastrointestinal disease 3. cytostatic or corticosteroid medication 4. glenohumeral osteoarthrosis grade iii or above (x-ray evaluation with present osteophytes according to kellgren-lawrence classification) 5. history of alcoholism, drug abuse, psychological or other emotional problems that are likely to invalidate informed consent 6. previous same shoulder surgery 7. a massive tendon tear involving the whole supraspinatus tendon and/or combined tear of two - three tendons ie. supraspinatus with infraspinatus or subscapularis tendon tear. 8. patients denial
study of alagebrium in patients with insulin-dependent type 1 diabetes and microalbuminuria

Conditions: Diabetes Mellitus, Type 1; Diabetic Nephropathy

Summary: based upon the preclinical evidence in models of diabetic nephropathy under conditions approximating both type i and ii diabetes, treatment with alagebrium appears to have favorable and advantageous effects on the biochemical, structural, pathological and functional hallmarks of diabetic nephropathy. the renoprotective effects of alagebrium in preclinical models favor the evaluation of this drug in patients with type i diabetes.

this study is a double-blind, randomized, placebo-controlled, parallel design trial enrolling 80 patients (2x40) with type 1 diabetes and microalbuminuria. patients will be randomized to either 200 mg alagebrium twice daily or placebo for a period of 24 weeks after an 8 week run-in period. there will be a 8 week run-out period. all patients will receive ramipril during the entire study period. efficacy measurements will be performed at baseline, at 12 weeks and at the end of the study. measurements for albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, age related markers and 24 hour blood pressure measurements will also be determined. a total of 9 visits will be performed during the entire study.

Eligibility criteria:
inclusion criteria: * insulin-dependent type 1 diabetes * age 18-65 years * diagnosis of established microalbuminuria * blood pressure \<140 mm hg, diastolic blood pressure \<90 mm hg * hba1c \<10% exclusion criteria: * body mass index \>40 kg/m2 * cardiovascular event within 6 months prior to screening * history of acute myocardial infarction within 12 months prior to screening * serum creatinine \>1.5 mg/dl * receiving chronic nonsteroidal anti-inflammatory therapy * receiving antihypertensive therapy except for angiotensin converting enzyme inhibitors or angiotensin receptor blockers * any significant systemic illnesses,medical conditions or abnormal laboratory values
adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced npc, in order to evaluate the value of adjuvant chemotherapy in nasopharyngeal carcinoma (npc) patients.

patients presented with non-keratinizing npc and stage t3-4n1m0/txn2-3m0 are randomly assigned to receive concurrent chemoradiotherapy plus adjuvant chemotherapy (investigational arm)or concurrent chemoradiotherapy (control arm). patients in both arms receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy. patients in the investigational arm receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on day 1 to 5) every four weeks for three cycles after completion of radiotherapy. patients are stratified according to the treatment centers. the primary end point was failure-free survival (ffs). secondary end points included overall survival (os), distant failure-free survival (d-ffs), locoregional failure-free survival (lr-ffs), the initial response rates after treatments, toxic effects and treatment compliance. all efficacy analyses were conducted in the intention-to-treat population; the safety population included only patients who received their randomly assigned treatment.

Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing carcinoma (according to world health organization (who) histologically type) 2. tumor staged as n2-3or t3-4n1 (according to 6th american joint committee on cancer staging system) 3. no evidence of distant metastasis (m0) 4. performance status: kps ≥70 5. with normal liver function test (alanine aminotransferase、aspartate aminotransferase ≤2.5×upper limit of normal) 6. renal: creatinine clearance ≥60ml/min 7. adequate marrow: leucocyte count ≥4000/μl, hemoglobin ≥80g/l and platelet count ≥100000/μl 8. written informed consent exclusion criteria: 1. who type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. 2. age ≥70 or \<18 3. with a history of renal disease 4. prior malignancy 5. previous chemotherapy or radiotherapy 6. patient is pregnant or lactating 7. unstable cardiac disease requiring treatment. 8. emotion disturbance

Keywords: nasopharyngeal carcinoma concurrent chemoradiotherapy adjuvant chemotherapy clinical trial
tracking technologies for the analysis of mobility in alzheimer's disease

Conditions: Dementia

Summary: the research is aimed at exploring the application of novel tracking technique for the study of spatial activity among dementia patients and its implication on their families. the study sample will be composed of three groups of volunteers, each including100 participants aged over 60 years. the first group will include mci (mild cognitive impairment) patients. the second group will include patients that suffer from mild dementia. the third group will include age matched healthy participants. the tracking equipment will be a gps apparatus of 450 gms that will be carried by the participants for 24 hours along 2-4 weeks. the gps data will be transferred via the cellular network to operator center at the hebrew university at jerusalem, and will be documented in assigned data files. this monitoring procedure will be held every year and along a period of five years. the impact of the patient behavior on the care giver will be studied by means of five interviews along the tracking period.


Eligibility criteria:
inclusion criteria: * patients with mci, alzheimer's disease, or mixed type dementia; or * healthy control subjects who meet the following criteria: * mini mental state (mmse) of at least 21 * age 60 years or older * patients with history of stroke which is not followed by cognitive decline may be included * fluent language skills exclusion criteria: * other dementias (e.g. vascular, frontotemporal, metabolic etc); * other major psychiatric disorders (e.g. major depression, schizophrenia); * substance abuse; * mmse 20 or less; * severe motor disturbances; * sensory deficits potentially affecting mobility; or * severe physical disorders (e.g. cancer, major operation)
comparison of biphasic human insulin 30 with biphasic insulin aspart in subjects with diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to compare the glycaemic control of biphasic insulin aspart (biasp) 70 and/or biasp 50 with biphasic human insulin (bhi) 30 treatment.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes * current treatment with bhi 30 twice daily as the only insulin therapy for at least 3 months, with or without combination with oral hypoglycaemic agents * body mass index (bmi) maximum 40.0 kg/m\^2 exclusion criteria: * history of drug or alcohol dependence * impaired hepatic function * impaired renal function * cardiac disease * proliferative retinopathy * total daily insulin dose at least 1.80 iu/kg
a study to evaluate the effect of famotidine and omeprazole on mk0518 (raltegravir) pharmacokinetics in human immunodeficiency virus (hiv)-infected patients (0518-054)

Conditions: HIV-1 Infection; HIV Infections

Summary: an open-label, 3-period, fixed-sequence study in a panel of 18 hiv-infected patients on mk0518 as part of a stable treatment regimen for hiv.


Eligibility criteria:
inclusion criteria: * patient is human immunodeficiency virus (hiv) positive * patient is taking an mk0518 (raltegravir) containing regimen * patient has not had any changes to his/her antiviral regimen in the last 2 weeks * patient who is of reproductive potential agrees to use an acceptable method of birth control * patients baseline health is stable exclusion criteria: * patient has a history of stroke or chronic seizures. * patient has a history of gastric bypass surgery * patient is pregnant of breastfeeding * patient consumes excessive amounts of caffeinated beverages daily * patient has had major surgery, donated blood, or participated in another investigational study in the past 4 weeks

Keywords: treatment experienced
early warning study of serum thioredoixn reductase activity in excised non-small cell lung cancers (ewsotrilc)

Conditions: Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage IIIA

Summary: in pre-clinical study, we found that serum thioredoxin reductase activity harbours huge difference after any kind of treatments, so we hypothesis that serum activity of thioredoxin reductase may be a warning markers in excised non-small lung cancers, serum activity of this enzyme may elevated before ct scan

this is a cooperative research project in thoracic surgery department and medical oncology department of affiliated cancer hospital of xiangya school of medicine central south university, and the state key laboratory for natural medicine and biomimetic drugs perking university. the primary objective is to measure the thioredoxin reductase activity in blood in staged(ⅰ\~ⅲa) non-small lung cancers, to study the warning relapse ability of thioredoxin reductase in blood. the secondary objective is to compare the warning relapse activity of blood thioredoxin reductase activity with carcinoembryonic antigen (cea) in subjects who received surgery. blood will be collected in subjects before surgery, 5 days after surgery, and every 3 months after surgery till 2 years, then every 6 months till 3 years, or collect blood till tumor relapse for the subjects at stage ⅰa and low risk ⅰb. blood will be collected before surgery, 5 days after surgery, before adjuvant chemotherapy, after 2 circles of all adjuvant chemotherapy, then every 3 months after adjuvant chemotherapy till 2 years, and every 6 months till 3 years, or collect blood till tumor relapse for the subjects of high risk ⅰb\~ⅲa, evaluation ct results every time collect blood samples.

Eligibility criteria:
inclusion criteria: * pathologically proven staged(ⅰ\~ⅲa) non-small cell lung cancer or ct scan shows resectable lung mass, fast pathology proved non-small cell lung cancer * receive surgery in thoracic oncology department affiliated cancer hospital of xiangya school of medicine central south university without contraindication of surgery * tumor treatment naive（except for surgery for cervical cancer and cutaneous squamous cell carcinoma 5 years before） * signed informed consent to provide blood and tissue for study exclusion criteria: * patients received antitumor treatment before * patients with contraindication of surgery or patients who need adjuvant chemotherapy with contraindication of chemotherapy * pregnant or breast feeding women

Keywords: non-small cell lung cancer thioredoxin reductase carcina embryonic antigen